The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial

Am Heart J. 2018 Jul:201:164-167. doi: 10.1016/j.ahj.2018.03.019. Epub 2018 Apr 4.

Abstract

In older patients (70 ± 7 years) with chronic well-compensated heart failure with preserved ejection and controlled blood pressure, 6 months treatment with aliskiren (direct renin inhibitor) showed non-significant trends for modest improvements in peak exercise oxygen consumption (14.9 ± 0.2 mL kg-1 min-1 versus 14.4 ± 0.2 mL kg-1 min-1; P = .10, trend) and ventilatory anaerobic threshold (888 ± 19 mL/min versus 841 ± 18 mL/min; P = .08).

Trial registration: ClinicalTrials.gov NCT00982033.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amides / therapeutic use*
  • Antihypertensive Agents
  • Blood Pressure / drug effects
  • Double-Blind Method
  • Exercise Tolerance / drug effects*
  • Female
  • Fumarates / therapeutic use*
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Humans
  • Male
  • Randomized Controlled Trials as Topic / methods*
  • Stroke Volume / physiology*

Substances

  • Amides
  • Antihypertensive Agents
  • Fumarates
  • aliskiren

Associated data

  • ClinicalTrials.gov/NCT00982033